NCT01435655View on ClinicalTrials.gov

The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Transthyretin Familial Amyloid Polyneuropathy
Interventions
DRUG

tafamidis

tafamidis meglumine 20 mg QD

Trial Locations (2)

860-8556

Kumamoto University Hospital/Department of Neurology, Kumamoto

390-8621

Shinshu University Hospital/Department of Medicine (Neurology and Reumatology), Matsumoto-shi

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01435655 - The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin | Biotech Hunter | Biotech Hunter